CTOs on the Move


 
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.exicuretx.com
  • 2430 North Halsted Street
    Chicago, IL USA 60614
  • Phone: 847.673.1700

Executives

Name Title Contact Details

Funding

Exicure raised $20M on 09/27/2017
Exicure raised $11.2M on 11/06/2017

Similar Companies

The Hamner Institutes for Health Sciences

The Hamner Institutes for Health Sciences is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Vision Therapies

Advanced Vision Therapies is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stratos Genomics

Stratos Group is dedicated to the conversion of science and technology into commercial solutions for the advancement of mankind and the protection of the environment. Also under the Stratos Group umbrella is Stratos Product Development. Stratos Product Development is a world leader in innovation and high tech product development services.

Plexium

Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.

Infinity Pharmaceuticals

Infinity Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.